All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
Glofit-GemOx vs R-GemOx for R/R DLBCL: Results from phase III STARGLO trial
Bookmark this article
|
Results from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL were published in The Lancet by Abramson et al.1 The primary efficacy endpoint was OS. |
| Key learnings |
| With a median follow-up of 11.3 months, OS was longer for Glofit-GemOx vs R-GemOx (HR, 0.59; 95% CI, 0.40–0.89; p = 0.011). |
| At a median follow-up of 20.1 months, the updated analysis showed that median OS (25.5 months vs 12.9 months; p = 0.0064) and median PFS (13.8 months vs 3.6 months; p < 0.0001) were higher for Glofit-GemOx vs R-GemOx. |
| Safety of Glofit-GemOx was consistent with the known safety profiles of the individual agents. AE rates were higher with Glofit-GemOx vs R-GemOx (100% vs 96%). CRS occurred in 44% of patients in the Glofit-GemOx group, and most were low grade (Grade 1, 31%; Grade 2, 10%; and Grade 3, 2%). |
| The efficacy and tolerable safety data from the phase III STRAGLO trial support the use of Glofit-GemOx in the treatment of patients with R/R DLBCL. |
Abbreviations: AE, adverse event; CI, confidence interval; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; Glofit-GemOx, glofitamab plus gemcitabine and oxaliplatin; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; R-GemOx, rituximab plus gemcitabine and oxaliplatin; R/R, relapsed/refractory.
- Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. The Lancet. 2024;404(10466):1940-1954. Online ahead of print. DOI: 10.1016/S0140-6736(24)01774-4
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
65 votes - 26 days left ...
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox